Trials / Completed
CompletedNCT02640092
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, longitudinal observational study evaluating the imaging characteristics of the tau positron-emission tomography (PET) radioligand \[18F\] Genentech Tau Probe 1 (GTP1) in the brain of participants with prodromal, mild, and moderate Alzheimer's disease (AD) compared to healthy participants. The overall goal of this protocol is to evaluate the longitudinal change in tau burden using \[18F\]GTP1, a tau targeted radiopharmaceutical.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]GTP1 | Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description. |
Timeline
- Start date
- 2015-12-23
- Primary completion
- 2019-06-11
- Completion
- 2019-06-11
- First posted
- 2015-12-28
- Last updated
- 2019-12-23
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02640092. Inclusion in this directory is not an endorsement.